title: Omega-3 fatty acids and HDL. How do they work in the prevention of cardiovascular disease?
abstract: Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) from marine origin have been strongly associated with cardiovascular protection, even at low doses ( < 1g/d). Despite the research performed in this promising area, basic aspects, such as the ideal doses and the mechanisms by which ω-3 PUFAs act, are not precisely defined. The best known biological property of ω-3 PUFAs is their hypotriglyceridemic effect, but other cardioprotective actions, such as reduction of arrhythmia susceptibility, antithrombotic, antiinflammatory and antioxidant effects, improvement of endothelial function, and delayed atherosclerosis development have received an increased interest in recent years. Some of these actions are also ascribable to high-density lipoproteins (HDL). Abundant epidemiological evidence links increasing HDL-cholesterol concentrations to cardiovascular protection. Recently, the protein cargo (proteome) of HDL particles has been attributed a key role in their functionality. In this review, we summarize the main effects of ω-3 PUFAs on HDL-cholesterol, HDL subfractions, and its main proteins, apolipoproteins (apo) AI and AII. The shared cardioprotective actions of ω-3 PUFAs and HDL are reviewed as well.
authors.affiliation: Laboratorio de Investigación Molecular, University Hospital Miguel Servet, Instituto de Investigación Sanitaria de Aragón, Zaragoza, Spain. civeira@unizar.es
authors.forename: Elena
authors.initials: E
authors.lastname: Burillo
authors.forename: Paula
authors.initials: P
authors.lastname: Martín-Fuentes
authors.forename: Rocío
authors.initials: R
authors.lastname: Mateo-Gallego
authors.forename: Lucía
authors.initials: L
authors.lastname: Baila-Rueda
authors.forename: Ana
authors.initials: A
authors.lastname: Cenarro
authors.forename: Emilio
authors.initials: E
authors.lastname: Ros
authors.forename: Fernando
authors.initials: F
authors.lastname: Civeira
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000378:metabolism / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D004281:Docosahexaenoic Acids / Q000378:metabolism / Q000627:therapeutic use; D015118:Eicosapentaenoic Acid / Q000378:metabolism / Q000627:therapeutic use; D015525:Fatty Acids, Omega-3 / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000178:diet therapy* / Q000378:metabolism; D008075:Lipoproteins, HDL / Q000097:blood* / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic
chemical_list: D000924:Anticholesteremic Agents; D015525:Fatty Acids, Omega-3; D008075:Lipoproteins, HDL; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid